Winegarden: ICER’s Cost Model ‘Wrong,’ ‘Dangerous’

Wayne Winegarden, senior fellow in business and economics at the Pacific Research Institute, says the Institute for Clinical and Economic Review’s (ICER) report on Gilead’s remdesivir is not only “wrong,” but also “dangerous.”

“This report throws out an arbitrary number that appears to have been rigorously calculated, but in reality is nothing more than a guess. Based on the errors noted above, an awfully bad guess at that,” Winegarden writes in an article published on Forbes. “Should policymakers listen to ICER, they will be punishing the private companies and individuals who are stepping up to help solve this pandemic.”

To read the full article, click here.